Abstract
IgA vasculitis (IgAV) is a pediatric disease with skin and systemic manifestations. Here, we conducted genome, transcriptome, and proteome-wide association studies in 2,170 IgAV cases and 5,928 controls, generated IgAV-specific maps of gene expression and splicing from blood of 255 pediatric cases, and reconstructed myeloid-specific regulatory networks to define disease master regulators modulated by the newly identified disease driver genes. We observed significant association at the HLA-DRB1 (OR=1.55, P=1.1×10−25) and fine-mapped specific amino-acid risk substitutions in DRβ1. We discovered two novel non-HLA loci: FCAR (OR=1.51, P=1.0×10−20) encoding a myeloid IgA receptor FcαR, and INPP5D (OR=1.34, P=2.2×10−09) encoding a known inhibitor of FcαR signaling. The FCAR risk locus co-localized with a cis-eQTL increasing FCAR expression; the risk alleles disrupted a PRDM1 binding motif within a myeloid enhancer of FCAR. Another risk locus was associated with a higher genetically predicted levels of plasma IL6R. The IL6R risk haplotype carried a missense variant contributing to accelerated cleavage of IL6R into a soluble form. Using systems biology approaches, we prioritized IgAV master regulators co-modulated by FCAR, INPP5D and IL6R in myeloid cells. We additionally identified 21 shared loci in a cross-phenotype analysis of IgAV with IgA nephropathy, including novel loci PAID4, WLS, and ANKRD55.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the NIH grants 1K01DK137031 (LL), 2R01DK105124 (KK, JN), 1RC2DK116690 (KK). JN and TJG are supported in part by NIH grants AI149431, DK078244, and DK082753. ATG was supported by the Ruth L. Kirschstein National Research Service Awards 5T32GM007367-43 and F30CA257765. The work of AK was supported by German Research Foundation (DFG) Project ID 431984000 (SFB 1453) and Project ID 390939984 (EXC-2189, CIBSS). The work of SMM was supported by the EQUIP Program for Medical Scientists, Faculty of Medicine, University of Freiburg. AC was supported by the NCI Outstanding Investigator award R35CA197745. The GIGA-kids Study was additionally supported by the Pediatric Nephrology Research Consortium (PNRC) and a gift from the IgA Nephropathy Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study participants provided informed consent to participate in genetic studies and the Institutional Review Board of Columbia University as well as local ethics review committees for each of the individual recruitment sites approved our study protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The genetic and transcriptomic data generated by this study is being deposited in dbGAP; the accession number will be provided before publication.
